BARX2
Homeobox protein BarH-like 2
Also known as: BARX2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9UMQ3
- Gene
- BARX2
- Ensembl
- ENSG00000043039
- Chromosome
- 11
- Canonical length
- 279 aa
- Protein class
- Predicted intracellular proteins, Transcription factors
- Subcellular location
- Nucleoplasm,Golgi apparatus,Cytosol
OverviewNCBI Gene
This gene encodes a member of the homeobox transcription factor family. A highly related protein in mouse has been shown to influence cellular processes that control cell adhesion and remodeling of the actin cytoskeleton in myoblast fusion and chondrogenesis. The encoded protein may also play a role in cancer progression. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
279 residues, UniProt reviewed canonical sequence.
>Q9UMQ3|BARX2
1 MHCHAELRLS SPGQLKAARR RYKTFMIDEI LSKETCDYFE KLSLYSVCPS LVVRPKPLHS
61 CTGSPSLRAY PLLSVITRQP TVISHLVPAT PGIAQALSCH QVTEAVSAEA PGGEALASSE
121 SETEQPTPRQ KKPRRSRTIF TELQLMGLEK KFQKQKYLST PDRLDLAQSL GLTQLQVKTW
181 YQNRRMKWKK MVLKGGQEAP TKPKGRPKKN SIPTSEEIEA EEKMNSQAQG QEQLEPSQGQ
241 EELCEAQEPK ARDVPLEMAE PPDPPQELPI PSSEPPPLSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against BARX2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.63
- Highest tissue expression
- 143 nTPM
Expression across tissuesHPA
Tissue
- esophagus: 143 nTPM
- salivary gland: 124 nTPM
- vagina: 66 nTPM
- cervix: 40 nTPM
- tongue: 37 nTPM
- skin: 31 nTPM
Single-cell type
- lacrimal acinar cells: 1,026 nCPM
- salivary acinar cells: 667 nCPM
- esophageal suprabasal cells: 516 nCPM
- esophageal apical cells: 363 nCPM
- pancreatic duct cells: 306 nCPM
- salivary ionocytes: 296 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- choroid plexus: 13 nTPM
- medulla oblongata: 8.3 nTPM
- white matter: 7.4 nTPM
- spinal cord: 5.4 nTPM
- midbrain: 5.2 nTPM
- pons: 4.8 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.69
- gnomAD pLI
- 0.21
- gnomAD missense Z
- -0.09
- DepMap mean gene effect
- 0.03
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cartilage condensation
- myotube differentiation
- negative regulation of transcription by RNA polymerase II
- positive regulation of transcription by RNA polymerase II
- regulation of transcription by RNA polymerase II
- skeletal muscle cell differentiation
- transcription by RNA polymerase II
Molecular functions
- chromatin binding
- DNA binding
- DNA-binding transcription activator activity, RNA polymerase II-specific
- DNA-binding transcription factor activity, RNA polymerase II-specific
- RNA polymerase II transcription regulatory region sequence-specific DNA binding
- sequence-specific double-stranded DNA binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads BARX2 as an antibody target. Whether an autoantibody or antibody against BARX2 could matter depends on whether native BARX2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
BARX2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label BARX2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...